EVFM · Evofem Biosciences, Inc.

The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/18/2022.

These shares were purchased in multiple transactions and the price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Dr. Greer's board and committee services.

The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Mr. Rutherford's board and committee services.

The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Dr. Kamdar's board and committee services.

The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Mr. O'Brien's board and committee services.

The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Dr. Rarick's board and committee services.

The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.

The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.

The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.

The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/3/2021.

The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/3/2021.

The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/3/2021.

Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on July 8, 2021. No shares were sold in connection with this transaction.

Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction.

Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction.

Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction.

Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction.

Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Mr. Rutherford's board and committee services.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Hall's board and committee services.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Greer's board and committee services.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Kamdar's board and committee services.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Rarick's board and committee services.

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Mr. O'Brien's board and committee services.

These purchases were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.21 to $2.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021.

The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2021.

The total amount of securities beneficially owned includes 2,800 shares of common stock the reporting person purchased in accordance with the 2019 ESPP based on 85% of the closing stock price on December 15, 2020, the last trading day of the purchase period.

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021.

The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2021.

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021.

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021.

The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2021.

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021.